Literature DB >> 11449025

Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease.

J R Slaughter1, K A Slaughter, D Nichols, S E Holmes, M P Martens.   

Abstract

To determine the extent to which depression complicates Parkinson's disease (PD), the authors analyzed the literature on depression in PD in order to report on its prevalence, clinical manifestations, and treatment. By means of MEDLINE literature searches, the analysis focused on 45 PD depression studies conducted from 1922 through 1998. The results indicate that the prevalence of depression is 31% for all PD patients. The clinical manifestations of PD depression include apathy, psychomotor retardation, memory impairment, pessimism, irrationality, and suicidal ideation without suicidal behavior. PD depression is effectively treated with a variety of antidepressants, most commonly at present the selective serotonin reuptake inhibitors. Anecdotal evidence supports the use of sertraline to treat PD depression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11449025     DOI: 10.1176/jnp.13.2.187

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  68 in total

1.  Nonrecognition of depression in Parkinson's disease.

Authors:  Karen E Anderson
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

Review 2.  Neuropsychiatric non-motor aspects of Parkinson's disease.

Authors:  B R Thanvi; S K Munshi; N Vijaykumar; T C N Lo
Journal:  Postgrad Med J       Date:  2003-10       Impact factor: 2.401

3.  Effects of depression and social support on comprehension and recall of informed consent information among Parkinson disease patients and their caregivers.

Authors:  Ellen J Teng; Nancy J Petersen; Christine Hartman; Ellen Matthiesen; Michael Kallen; Karon F Cook; Marvella E Ford
Journal:  Int J Psychiatry Med       Date:  2012       Impact factor: 1.210

4.  Executive function in Parkinson's disease: contributions of the dorsal frontostriatal pathways to action and motivation.

Authors:  Susan M Ravizza; John Goudreau; Mauricio R Delgado; Sandra Ruiz
Journal:  Cogn Affect Behav Neurosci       Date:  2012-03       Impact factor: 3.282

5.  Effects of Parkinson's Disease on Fundamental Frequency Variability in Running Speech.

Authors:  Leah K Bowen; Gabrielle L Hands; Sujata Pradhan; Cara E Stepp
Journal:  J Med Speech Lang Pathol       Date:  2013-09

6.  Pharmacotherapy of Parkinson's disease in Germany.

Authors:  J C Möller; Y Körner; R C Dodel; C Meindorfner; K Stiasny-Kolster; A Spottke; H P Krüger; W H Oertel
Journal:  J Neurol       Date:  2005-03-16       Impact factor: 4.849

7.  Depression and intelligence in patients with Parkinson's disease and deep-brain stimulation.

Authors:  Courtney R Schadt; Katie L Cox; Michael G Tramontana; Daniel W Byrne; Thomas L Davis; John Y Fang; Peter E Konrad; Bhavna Padaliya; Robert W Mutter; Chandler E Gill; Caralee R Richardson; P David Charles
Journal:  J Natl Med Assoc       Date:  2006-07       Impact factor: 1.798

8.  Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample.

Authors:  Peijun Chen; Helen C Kales; Daniel Weintraub; Frederic C Blow; Lan Jiang; Alan M Mellow
Journal:  J Geriatr Psychiatry Neurol       Date:  2007-09       Impact factor: 2.680

9.  Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies.

Authors:  P Cédric M P Koolschijn; Neeltje E M van Haren; Gerty J L M Lensvelt-Mulders; Hilleke E Hulshoff Pol; René S Kahn
Journal:  Hum Brain Mapp       Date:  2009-11       Impact factor: 5.038

Review 10.  Parkinson disease: an update.

Authors:  Steven J Frucht
Journal:  Neurologist       Date:  2004-07       Impact factor: 1.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.